Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis

Lü,Mu-Han; Deng,Jia-Qi; Cao,Ya-Ling; Fang,Dian-Chun; Zhang,Yao; Yang,Shi-Ming

doi:10.3892/etm.2012.471

Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis

Authors:
- Mu-Han Lü
- Jia-Qi Deng
- Ya-Ling Cao
- Dian-Chun Fang
- Yao Zhang
- Shi-Ming Yang
View Affiliations

Affiliations: Institute of Gastroenterology, Third Military Medical University, Chongqing 400038, P.R. China, School of Foreign Languages, Lu Zhou Medical College, Luzhou 646000, P.R. China, Department of Epidemiology, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: February 3, 2012 https://doi.org/10.3892/etm.2012.471
Pages: 728-734

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of telomerase is involved in carcinogenesis in most types of cancers. However, the prognostic value of telomerase activity (TA) in patients with gastric carcinoma (GC) remains controversial. We conducted a meta-analysis to assess the relationship between TA and the clinical outcome of GC. A meta-analysis of 18 studies (886 patients) was performed to evaluate the association between TA and metastasis-related parameters in GC patients by searching databases, including PubMed, MEDLINE, EMBASE, Web of Science databases, Cochrane Library and the Chinese Biomedical Literature database (CBM) (last search updated in October 2011). We used the odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association between TA and metastasis of GC. Our analysis results indicated that high telomerase activity expression tended to be associated with the presence of lymph node metastasis (866 patients) (OR=2.03, 95% CI 1.21-3.39, p=0.007), the depth of invasion (886 patients) (OR=1.87, 95% CI 1.30-2.70, p=0.0007), distant metastasis (407 patients) (OR=2.71, 95% CI 1.59-4.63, p=0.0002), tumor size (466 patients) (OR=2.14, 95% CI 1.31‑3.50, p=0.002) and TNM stage (711 patients) (OR=2.39, 95% CI 1.30-4.41, p=0.005). However, high TA expression was not associated with the presence of histologic differentiation (791 patients) (OR=1.51, 95% CI 0.73-3.11, p=0.26). In conclusion, telomerase overexpression not only plays a key role in primary initiation, but also promotes invasion and metastatic progression of GC. These findings raise the possibility of using TA to screen for the prognosis of gastric cancer.

View Figures

View References

1.	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl 1): 5–11. 2002. View Article : Google Scholar
2.	Yokota J: Tumor progression and metastasis. Carcinogenesis. 21:497–503. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Greider CW and Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature. 337:331–337. 1989. View Article : Google Scholar : PubMed/NCBI
4.	Sealey DC, Zheng L, Taboski MA, Cruickshank J, Ikura M and Harrington LA: The N-terminus of hTERT contains a DNA-binding domain and is required for telomerase activity and cellular immortalization. Nucleic Acids Res. 38:2019–2035. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Catarino R, Araujo A, Coelho A, Gomes M, Nogueira A, Lopes C and Medeiros RM: Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clin Cancer Res. 16:3706–3712. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, Braun Y, Schuck A, Lanvers C, Bankfalvi A, et al: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 198:181–189. 2002. View Article : Google Scholar
7.	Horvai AE, Kramer MJ, Garcia JJ and O'Donnell RJ: Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol. 21:423–430. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283:2008–2012. 2000. View Article : Google Scholar
9.	Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, et al: Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 156:300–310. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN and Kleijnen J: Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 6:92006. View Article : Google Scholar : PubMed/NCBI
12.	Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas. 20:37–46. 1960. View Article : Google Scholar
13.	Greenland S and Robins J: Estimation of a common effect parameter from sparse follow-up data. Biometrics. 41:55–68. 1990. View Article : Google Scholar : PubMed/NCBI
14.	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
15.	Yang SM, Fang DC, Luo YH, Lu R, Battle PD and Liu WW: Alterations of telomerase activity and terminal restriction fragment in gastric cancer and its premalignant lesions. J Gastroenterol Hepatol. 16:876–882. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Hu X, Wu H, Zhang S, Yuan H and Cao L: Clinical significance of telomerase activity in gastric carcinoma and peritoneal dissemination. J Int Med Res. 37:1127–1138. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Wu CH, Lin SR, Yu FJ, Wu DC, Pan YS, Hsieh JS, Huang SY and Wang JY: Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer. 119:373–379. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Wang W, Luo HS and Yu BP: Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. World J Gastroenterol. 10:177–181. 2004.PubMed/NCBI
19.	Yoo J, Park SY, Kang SJ, Kim BK, Shim SI and Kang CS: Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas. Mod Pathol. 20:700–707. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Yasui W, Tahara H, Tahara E, Fujimoto J, Nakayama J, Ishikawa F and Ide T: Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas. Jpn J Cancer Res. 89:1099–1103. 1998. View Article : Google Scholar : PubMed/NCBI
21.	Kameshima H, Yagihashi A, Yajima T, Kobayashi D, Denno R, Hirata K and Watanabe N: Helicobacter pylori infection: augmentation of telomerase activity in cancer and noncancerous tissues. World J Surg. 24:1243–1249. 2000. View Article : Google Scholar
22.	Gigek CO, Leal MF, Silva PN, Lisboa LC, Lima EM, Calcagno DQ, Assumpcao PP, Burbano RR and Smith Mde A: hTERT methylation and expression in gastric cancer. Biomarkers. 14:630–636. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Hu LH, Chen FH, Li YR and Wang L: Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J Gastroenterol. 10:3514–3517. 2004.PubMed/NCBI
24.	Ahn MJ, Noh YH, Lee YS, Lee JH, Chung TJ, Kim IS, Choi IY, Kim SH, Lee JS and Lee KH: Telomerase activity and its clinicopathological significance in gastric cancer. Eur J Cancer. 33:1309–1313. 1997. View Article : Google Scholar : PubMed/NCBI
25.	Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW and Matsuura Y: Telomerase activity in gastric cancer. Cancer Res. 55:3258–3262. 1995.PubMed/NCBI
26.	Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T and Tahara E: Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res. 1:1245–1251. 1995.PubMed/NCBI
27.	Liu Xl, Chen P and Wei JM: The relationship between CK20 mRNA and hTERT mRNA expression in peripheral blood of patients with gastric carcinoma and tumor micrometastasis. Chin J Clin Oncol. 35:1286–1289. 2008.
28.	Okusa Y, Shinomiyo N, Ichikura T and Mochizuki H: Correlation between telomerase activity and DNA ploidy in gastric cancer. Oncology. 55:258–264. 1998. View Article : Google Scholar : PubMed/NCBI
29.	Shin JH, Chung J, Kim HO, Kim YH, Hur YM, Rhim JH, Chung HK, Park SC, Park JG and Yang HK: Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs. Aliment Pharmacol Ther. 16(Suppl 2): 137–144. 2002. View Article : Google Scholar : PubMed/NCBI
30.	Mori N, Oka M, Hazama S, Iizuka N, Yamamoto K, Yoshino S, Tangoku A, Noma T and Hirose K: Detection of telomerase activity in peritoneal lavage fluid from patients with gastric cancer using immunomagnetic beads. Br J Cancer. 83:1026–1032. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Zhan WH, Ma JP, Peng JS, Gao JS, Cai SR, Wang JP, Zheng ZQ and Wang L: Telomerase activity in gastric cancer and its clinical implications. World J Gastroenterol. 5:316–319. 1999.PubMed/NCBI
32.	Gümüx-Akay G, Ünal AE, Bayar S, Karadayi K, Elhan AH, Sunguroqlu A and Tükün A: Telomerase activity could be used as a marker for neoplastic transformation in gastric adenocarcinoma: but it does not have a prognostic significance. Genet Mol Res. 6:41–49. 2007.(In Bulgarian).
33.	Bulanov D: Gastric Cancer – Current state of the problem. Part I. Epidemiology. Pathology. Classification. Staging. Khirurgiia (Sofia). 48–59. 2007.(In Bulgarian).
34.	Beisner J, Dong M, Taetz S, Nafee N, Griese EU, Schaefer U, Lehr CM, Klotz U and Murdter TE: Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Lung Cancer. 68:346–354. 2010.
35.	Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D and Yu H: Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 13:R562011. View Article : Google Scholar : PubMed/NCBI
36.	Nakamura M, Saito H, Ebinuma H, Wakabayashi K, Saito Y, Takagi T, Nakamoto N and Ishii H: Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J Cell Physiol. 187:392–401. 2001. View Article : Google Scholar : PubMed/NCBI
37.	Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, Durante C and Pacini F: Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab. 93:3950–3957. 2008. View Article : Google Scholar
38.	Miyachi K, Fujita M, Tanaka N, Sasaki K and Sunagawa M: Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J Exp Clin Cancer Res. 21:269–275. 2002.PubMed/NCBI
39.	Gumus-Akay G, Elhan AH, Unal AE, Demirkazik A, Sunguroglu A and Tukun A: Effects of genomic imbalances on telomerase activity in gastric cancer: clues to telomerase regulation. Oncol Res. 17:455–462. 2009. View Article : Google Scholar : PubMed/NCBI
40.	Usselmann B, Newbold M, Morris AG and Nwokolo CU: Telomerase activity and patient survival after surgery for gastric and oesophageal cancer. Eur J Gastroenterol Hepatol. 13:903–908. 2001. View Article : Google Scholar : PubMed/NCBI
41.	Poole JC, Andrews LG and Tollefsbol TO: Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 269:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
42.	Jin X, Beck S, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Choi YJ and Kim H: Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor. Exp Mol Med. 42:574–582. 2010. View Article : Google Scholar : PubMed/NCBI
43.	Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, et al: Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci USA. 103:11306–11311. 2006. View Article : Google Scholar : PubMed/NCBI
44.	Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW and Herbert BS: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res. 12:3184–3192. 2006. View Article : Google Scholar : PubMed/NCBI
45.	Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ and Park C: High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 88:144–152. 2008. View Article : Google Scholar : PubMed/NCBI
46.	Yu ST, Chen L, Wang HJ, Tang XD, Fang DC and Yang SM: hTERT promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol. 35:329–336. 2009.PubMed/NCBI
47.	Palli D: Epidemiology of gastric cancer. Ann Ist Super Sanita. 32:85–99. 1996.
48.	Soler RE, Leeks KD, Razi S, Hopkins DP, Griffith M, Aten A, Chattopadhyay SK, Smith SC, Habarta N, Goetzel RZ, et al: A systematic review of selected interventions for worksite health promotion. The assessment of health risks with feedback. Am J Prev Med. 38:S237–S262. 2010. View Article : Google Scholar : PubMed/NCBI